Page last updated: 2024-12-10

a 65186

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A 65186: type A CCK receptor antagonist; structure given in first source; A-70104 is the dicyclohexylammonium salt of A-65186 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081191
CHEMBL ID112307
SCHEMBL ID5931137
MeSH IDM0174225

Synonyms (14)

Synonym
a 70104
a-70104
pentanoic acid, 5-(dipentylamino)-5-oxo-4-((3-quinolinylcarbonyl)amino)-, (r)-
n-3-quinolinoyl-glutamyl-n,n-alpha-di-n-pentylamine
119295-94-2
a 65186
CHEMBL112307 ,
a-65186
(4r)-5-(dipentylamino)-5-oxo-4-(quinoline-3-carbonylamino)pentanoic acid
bdbm50008629
4-dipentylcarbamoyl-4-[(quinoline-3-carbonyl)-amino]-butyric acid
SCHEMBL5931137
DTXSID80152399
AKOS040747708
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)IC50 (µMol)1.17010.00041.13803.5000AID52432; AID52433; AID52573
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID52433Compound was evaluated for the binding affinity against Cholecystokinin type A receptor in pancreatic acinar cell1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
AID52573Inhibition of [125I]Bolton-Hunter CCK-8 binding to cholecystokinin type A receptor in guinea pig pancreatic membranes.1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.
AID52432Compound was evaluated for the binding affinity against Cholecystokinin type A receptor in cortical cells.1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
AID76390Inhibition of CCK-8-stimulated amylase release1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.
AID157518Compound was evaluated for the ability to inhibit CCK-stimulated amylase release in pancreatic acinar cells of guinea pig1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.76)18.7374
1990's6 (35.29)18.2507
2000's6 (35.29)29.6817
2010's3 (17.65)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]